Archive for the ‘Arthritis’ Category

Some Patients May Be Spared An Unnecessary Procedure By New Test For Joint Infection

Tuesday, March 4th, 2008

A potential diagnostic test that could help surgeons confirm or rule out the presence of infection-causing bacteria in prosthetic joints that require surgical revision has been developed by researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH). ...

Detecting Bone Erosion In Rheumatoid Arthritis

Thursday, February 28th, 2008

Both magnetic resonance imaging (MRI) and computed tomography (CT) are more sensitive than radiography - the standard imaging technique - for detecting bone erosions in rheumatoid arthritis (RA), according to research published in the open access journal Arthritis Research & Therapy. The early detection of bone erosions is crucial for ...

NICE Launches New Era For Millions With Osteoarthritis, UK

Thursday, February 28th, 2008

In guidelines hailed by Arthritis Care as a giant leap towards more patient-centred services, the National Institute of Health and Clinical Excellence (NICE) today recommends that osteoarthritis (OA) patients needing NHS joint surgery are referred promptly when other treatments have failed them. For the first time, NICE stipulates that ...

Arthritis Sufferers Fund Arthritis Research

Monday, February 18th, 2008

The Queensland and Northern New South Wales Lions Medical Research Foundation, long time supporters of the Brisbane research community, have confirmed funding of $1.2 million for scientists at UQ's Diamantina Institute. Dr Gethin Thomas will be the inaugural recipient of the $300,000 three-year fellowship, which will fund his ...

Non-Invasive Imaging Method For Diagnosing Osteoarthritis

Tuesday, February 12th, 2008

Researchers at New York University and Tel Aviv University have developed a non-invasive imaging method that can be used to diagnose and monitor a number of diseases, including osteoarthritis and inter-vertebral disc degeneration, in their early stages. Their work appears in the latest issue of the journal Proceedings of the ...

Randox Introduces A Range Of 25 Liquid And Ready-To-Use Protein Assays

Monday, February 4th, 2008

Randox have introduced a range of 25 liquid and ready-to-use protein assays. Clinicians use protein assays to diagnose and monitor a diverse range of diseases and conditions such as diabetes, arthritis and anaemia. Randox protein assays are manufactured to meet high performance specifications. The assays have wide ranges, ...

A Pathway Discovered To Turn Off Immune System Cells

Friday, February 1st, 2008

University of Minnesota researchers have discovered a new way to turn genes off in human T cells, a type of white blood cell that helps the immune system fight infections.Turning off genes, through a process known as mRNA decay, is important for regulating the body's immune response after fighting infection. ...

Rheumatic Complaints Not Just A Problem For The Western World

Friday, February 1st, 2008

We like to complain about our aches and pains, but rheumatism is not only the preserve of western society. A comprehensive survey of rheumatic diseases in China, published in the open access journal Arthritis Research & Therapy, reveals that rheumatic complaints are also common in China. The survey suggests that ...

Bone Medical Developing Potentially First Rheumatoid Arthritis Drug To Treat Both IL6 And TNF, Australia

Tuesday, January 29th, 2008

New data from the Bone Medical Ltd (ASX: BNE) rheumatoid arthritis (RA) programme shows that its lead drug candidate BN006 is capable not only of down-regulating TNF secretion, but also of inhibiting secretion of IL6. BN006 has been developed as an inhibitor of secretion of TNF, one of the ...

Arthritis Foundation Launches Year-Long Recognition Of 60th Anniversary

Monday, January 28th, 2008

The Arthritis Foundation began a year-long observance of 60 years as the nation's leading organization dedicated to ending the pain, disability devastation of arthritis. While great strides have been made in the treatment and understanding of arthritis, the disease remains the most common form of disability in the U.S. "The ...

Genentech And Biogen Idec Announce Positive Results From A Phase 3 Trial Of Rituxan In Patients With Rheumatoid Arthritis Who Inadequately Responded

Monday, January 28th, 2008

Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III clinical study of Rituxan® (rituximab) in biologic-na?ve patients met its primary endpoint of a significantly greater proportion of Rituxan-treated patients achieving an American College of Rheumatology (ACR) 20 response at week 24, compared to placebo. The ...

Although Comfort And Mobility Improved, Arthritic Knees Remain Painful After Arthroscopic Surgery

Saturday, January 26th, 2008

Trimming damaged tissue through arthroscopic surgery does not relieve pain and swelling in arthritic knees any better than simply flushing loose debris from the joint, according to a new review of evidence.However, these findings come from studies on a broad range of patients. The technique, known as arthroscopic debridement (AD), ...

Arthritis Foundation Announces Top 10 Arthritis Advances Of 2007

Thursday, January 24th, 2008

A team of engineers have recently created a new framework upon which cartilage tissue can be grown. The novel scaffold is porous, so the fabric can be seeded with cells and transplanted into a joint damaged by arthritis. The woven "fabric" will be absorbed by the body, ...

Breakthrough Offers Potential Treatment For Rheumatoid Arthritis

Thursday, January 3rd, 2008

A breakthrough in understanding the way atoms move across cell membranes in the human body could pave the way for the development of new treatments for inflammatory diseases such as rheumatoid arthritis.Scientists at the University of Leeds have identified a previously unknown natural mechanism that opens ion channels - proteins ...

MorphoSys Files Clinical Trial Application To Initiate First Phase 1 Clinical Study Of Its MOR103 Program For Rheumatoid Arthritis Treatment

Saturday, December 29th, 2007

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that it has submitted a clinical trial application (CTA) to initiate a phase 1 trial using the HuCAL-derived antibody MOR103 for the treatment of Rheumatoid Arthritis. MorphoSys plans to reveal the target molecule of its lead antibody program MOR103 and ...